{'fraction_non_alphanumeric': 0.035175879396984924, 'fraction_numerical': 0.010050251256281407, 'mean_word_length': 6.97, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Recombinant human Tissue Inhibitor of Metalloprotease −2; a novel anti‐cancer therapeutic

Tissue inhibitor of Metalloprotease‐2 (TIMP‐2), a soluble endogenous ~22 kDa metalloprotease inhibitor, exhibits anti‐cancer properties by metalloprotease inhibition in tumor microenvironment, direct receptor‐mediated growth inhibition, increased chemo –sensitivity and decreased cell motility. Herein we report a complete production‐characterization process, biophysical analysis, anti‐MMP activity and anti‐proliferative activity of rhTIMP‐2 in cell lines and mouse models of breast and lung cancer. Further we report the development and characterization of rhTIMP‐2 extended release peptide hydrogels and desferoxamine(des) labelled rhTIMP‐2 for dosage form and PET scan probe development respectively.